Enrichment of nano delivery platforms for mRNA-based nanotherapeutics

作     者：Xiao Liu Xu Zhang Jiulong Li Huan Meng Xiao Liu;Xu Zhang;Jiulong Li;Huan Meng

作者机构：Department of GastroenterologyBeijing HospitalNational Center of GerontologyInstitute of Geriatrics MedicineChinese Academy of Medical SciencesBeijingChina CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience National Center for Nanoscience and TechnologyBeijingChina University of Chinese Academy of SciencesBeijingChina CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology11 ZhongguancunbeiyitiaoHaidian DistrictBeijing 100190China University of Chinese Academy of SciencesBeijing 100049China 

出 版 物：《Medical Review》 (医学评论（英文）)

年 卷 期：2023年第3卷第4期

页      面：356-361页

学科分类：1006[医学-中西医结合] 1002[医学-临床医学] 07[理学] 070205[理学-凝聚态物理] 08[工学] 080501[工学-材料物理与化学] 0805[工学-材料科学与工程（可授工学、理学学位）] 100602[医学-中西医结合临床] 0702[理学-物理学] 10[医学] 

基　　金：supported by National Key Research and Development Program of China(2022YFA1207300) National High-Level Hospital Clinical Research Funding(BJ-2022-103) National Natural Science Foundation of China(32271452) supported by the Strategic Priority Research Program of the Chinese Academy of Sciences(XDB36000000) CAS Project for Young Scientists in Basic Research,Grant No.YSBR-036CAS Innovation team science award 

主　　题：high throughput screening mRNA nano/bio interface nano drug delivery system non-LNP nanocarrier nanosafety 

摘      要：Lipid-based nanoparticles(LNP)have shown significant progress in delivering mRNA for therapeutics,particularly with the success of coronavirus disease 2019(COVID-19)***,there are still challenges,such as organ-specific targeting,sustained protein expression,immunogenicity,and storage that need to be ***,there is interest in developing additional nano drug delivery systems(DDS)to complement LNP *** of these include polymer,lipid-polymer hybrid,organic/inorganic hybrid nanostructure,and inorganic *** our opinion,LNP technology may not be suitable for every disease scenario in categories such as infection disease,cancer,pulmonary disease,autoimmune disorders and genetic rare disease(among others).This is because different diseases may require distinct administration routes,doses,and treatment durations,as well as considerations for biological barriers that may lower the efficacy and/or exert safety *** this perspective,we will highlight the need and potential for enhancing the diversity of nano delivery platforms for mRNA-based nanotherapeutics.